Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:COLL NASDAQ:JBIO NASDAQ:MRVI NASDAQ:NVCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$34.42+0.6%$34.34$28.34▼$50.79$1.12B0.76502,235 shs206,521 shsJBIOJade Biosciences$23.46+0.5%$19.38$6.57▼$28.00$1.16B1.52460,122 shs368,826 shsMRVIMaravai LifeSciences$4.48+1.1%$3.48$1.99▼$4.99$1.16B0.621.75 million shs2.63 million shsNVCTNuvectis Pharma$10.94+2.9%$8.96$5.55▼$13.34$290.24M-0.1171,420 shs99,061 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+1.78%-1.86%-0.26%-24.26%+14.22%JBIOJade Biosciences+6.67%-6.90%-0.68%+60.41%+2,333,999,900.00%MRVIMaravai LifeSciences+4.98%+1.37%+22.71%+43.83%+84.58%NVCTNuvectis Pharma+3.20%-11.71%+27.61%+24.91%-0.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOLLCollegium Pharmaceutical$34.42+0.6%$34.34$28.34▼$50.79$1.12B0.76502,235 shs206,521 shsJBIOJade Biosciences$23.46+0.5%$19.38$6.57▼$28.00$1.16B1.52460,122 shs368,826 shsMRVIMaravai LifeSciences$4.48+1.1%$3.48$1.99▼$4.99$1.16B0.621.75 million shs2.63 million shsNVCTNuvectis Pharma$10.94+2.9%$8.96$5.55▼$13.34$290.24M-0.1171,420 shs99,061 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCOLLCollegium Pharmaceutical+1.78%-1.86%-0.26%-24.26%+14.22%JBIOJade Biosciences+6.67%-6.90%-0.68%+60.41%+2,333,999,900.00%MRVIMaravai LifeSciences+4.98%+1.37%+22.71%+43.83%+84.58%NVCTNuvectis Pharma+3.20%-11.71%+27.61%+24.91%-0.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOLLCollegium Pharmaceutical 2.67Moderate Buy$57.5067.05% UpsideJBIOJade Biosciences 2.89Moderate Buy$34.3346.35% UpsideMRVIMaravai LifeSciences 2.50Moderate Buy$5.5022.77% UpsideNVCTNuvectis Pharma 2.00Hold$10.00-8.59% DownsideCurrent Analyst Ratings BreakdownLatest NVCT, COLL, JBIO, and MRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026MRVIMaravai LifeSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/11/2026JBIOJade Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$23.00 ➝ $32.005/11/2026JBIOJade Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $34.005/8/2026MRVIMaravai LifeSciences Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.005/8/2026MRVIMaravai LifeSciences Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.50 ➝ $5.504/27/2026JBIOJade Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $45.004/24/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)4/10/2026JBIOJade Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026JBIOJade Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/25/2026JBIOJade Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $35.00(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOLLCollegium Pharmaceutical$780.57M1.43$15.57 per share2.21$9.63 per share3.57JBIOJade BiosciencesN/AN/AN/AN/A$6.01 per shareN/AMRVIMaravai LifeSciences$185.74M6.23$0.44 per share10.08$1.43 per share3.13NVCTNuvectis PharmaN/AN/AN/AN/A$0.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOLLCollegium Pharmaceutical$62.87M$2.0416.875.82N/A9.41%95.18%16.39%8/6/2026 (Estimated)JBIOJade Biosciences-$127.41M-$2.02N/AN/AN/AN/A-51.34%-47.32%N/AMRVIMaravai LifeSciences-$130.77M-$0.71N/AN/AN/A-51.07%-17.87%-9.08%N/ANVCTNuvectis Pharma-$26.44M-$1.31N/AN/AN/AN/A-161.00%-98.88%8/4/2026 (Estimated)Latest NVCT, COLL, JBIO, and MRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026COLLCollegium Pharmaceutical$1.52$1.76+$0.24$0.40$184.47 million$193.52 million5/7/2026Q1 2026JBIOJade Biosciences-$0.52-$0.57-$0.05-$0.57N/AN/A5/7/2026Q1 2026MRVIMaravai LifeSciences-$0.05$0.01+$0.06-$0.02$53.00 million$65.84 million5/5/2026Q1 2026NVCTNuvectis Pharma-$0.30-$0.26+$0.04-$0.26N/AN/A3/6/2026Q4 2025JBIOJade Biosciences-$0.45-$0.11+$0.34-$0.11N/AN/A2/26/2026Q4 2025COLLCollegium Pharmaceutical$2.20$2.04-$0.16$0.46$206.36 million$205.45 million2/25/2026Q4 2025MRVIMaravai LifeSciences-$0.07-$0.04+$0.03-$0.24$49.06 million$49.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCOLLCollegium PharmaceuticalN/AN/AN/AN/AN/AJBIOJade BiosciencesN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOLLCollegium Pharmaceutical2.471.711.62JBIOJade BiosciencesN/A14.2914.29MRVIMaravai LifeSciences0.725.914.96NVCTNuvectis PharmaN/A2.272.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOLLCollegium PharmaceuticalN/AJBIOJade BiosciencesN/AMRVIMaravai LifeSciences50.25%NVCTNuvectis Pharma96.77%Insider OwnershipCompanyInsider OwnershipCOLLCollegium Pharmaceutical1.85%JBIOJade Biosciences23.06%MRVIMaravai LifeSciences2.49%NVCTNuvectis Pharma30.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCOLLCollegium Pharmaceutical21032.43 million31.83 millionOptionableJBIOJade Biosciences2049.36 million37.98 millionN/AMRVIMaravai LifeSciences610258.19 million251.76 millionOptionableNVCTNuvectis Pharma826.53 million18.43 millionNot OptionableNVCT, COLL, JBIO, and MRVI HeadlinesRecent News About These CompaniesNuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 14, 2026 | globenewswire.comWall Street Zen Upgrades Nuvectis Pharma (NASDAQ:NVCT) to "Hold"May 9, 2026 | marketbeat.comWall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to TradeMay 7, 2026 | zacks.comHC Wainwright Boosts Earnings Estimates for Nuvectis PharmaMay 7, 2026 | marketbeat.comNuvectis Pharma (NASDAQ:NVCT) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPSMay 5, 2026 | marketbeat.comNuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsMay 5, 2026 | globenewswire.comInsider Stock Buying Reaches US$2.07m On Nuvectis PharmaMay 4, 2026 | finance.yahoo.comNuvectis Pharma (NVCT) price target decreased by 11.71% to 16.66April 28, 2026 | msn.comNuvectis Pharma (NVCT) Projected to Post Earnings on TuesdayApril 28, 2026 | marketbeat.comNuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research MeetingMarch 31, 2026 | globenewswire.comHere's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn SituationMarch 24, 2026 | finance.yahoo.comNuvectis Pharma Reports 2025 Financial Results and Progress in NXP900 Development ProgramFebruary 11, 2026 | quiverquant.comQNuvectis Pharma, Inc. Reports 2025 Financial Results and Business HighlightsFebruary 11, 2026 | globenewswire.comNuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s WhyDecember 27, 2025 | defenseworld.netDNuvectis Pharma announces initiation of Phase 1b study of NXP900December 17, 2025 | msn.comNuvectis Pharma Initiates Phase 1b Study of NXP900 in Combination with Osimertinib for EGFRmut+ NSCLC PatientsDecember 17, 2025 | quiverquant.comQNuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLCDecember 17, 2025 | globenewswire.comNuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insidersDecember 5, 2025 | finance.yahoo.comRoth MKM Sticks to Their Buy Rating for Nuvectis Pharma (NVCT)December 5, 2025 | theglobeandmail.comNuvectis Pharma to Host Key Opinion Leader Meeting on NXP900 Phase 1b Program in Advanced Solid TumorsNovember 25, 2025 | quiverquant.comQNuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLCNovember 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026The Trade Desk: Down 75%, But a Reversal May Be NearBy Sam Quirke | April 25, 20265 Reasons Rambus Stock Price Collapse Is One Hot Entry PointBy Thomas Hughes | May 1, 2026The Power Grid Is Dying—Is It Time to Buy Its Replacement?By Jeffrey Neal Johnson | May 15, 2026TMC Forges a New EV Supply Chain at the Bottom of the SeaBy Jeffrey Neal Johnson | May 12, 2026NVCT, COLL, JBIO, and MRVI Company DescriptionsCollegium Pharmaceutical NASDAQ:COLL$34.42 +0.20 (+0.58%) Closing price 04:00 PM EasternExtended Trading$34.41 -0.01 (-0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Jade Biosciences NASDAQ:JBIO$23.46 +0.12 (+0.51%) Closing price 04:00 PM EasternExtended Trading$23.47 +0.01 (+0.04%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Maravai LifeSciences NASDAQ:MRVI$4.48 +0.05 (+1.13%) Closing price 04:00 PM EasternExtended Trading$4.49 +0.00 (+0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Nuvectis Pharma NASDAQ:NVCT$10.94 +0.31 (+2.92%) Closing price 04:00 PM EasternExtended Trading$11.20 +0.26 (+2.37%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
